Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

82.35GBp
21 Feb 2019
Change (% chg)

0.50 (+0.61%)
Prev Close
81.85
Open
83.65
Day's High
83.65
Day's Low
81.55
Volume
172,426
Avg. Vol
970,810
52-wk High
107.80
52-wk Low
65.85

Select another date:

Thu, Jan 3 2019

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

UPDATE 3-Vectura hopes new respiratory device will breathe life into business

* Forecasts 2018 adjusted core earnings above market forecasts

UK drugmaker Vectura expects 2018 earnings to top market forecasts

Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

UPDATE 2-Vectura drops severe asthma treatment after poor trial results

* Shares fall more than 10 percent (Adds CEO, analyst comment, share movement)

Vectura to stop developing asthma treatment after late-stage failure

Nov 26 British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.

Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a "no-deal" Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.

Select another date: